On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...

The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by ...

Since the 2023 financing round, Flare’s lead program FX-909 has moved into a phase 1 clinical trial for patients with ...

"Big Pharma" stocks took a tumble this morning following the news that President-elect Donald Trump has appointed Robert F.

Turner, a seasoned biotechnology executive, was formerly CEO of Carmot Therapeutics, which was acquired by Roche in 2024 for ...

CEO of Roche Pharmaceuticals, said during a press conference Wednesday. In the third quarter, Vabysmo’s sales grew by 56% year over year to surpass 1 billion Swiss francs ($1.2 billion).

Hoffmann-La Roche Limited (Roche Canada) is pleased to announce, with support from the Government of Ontario through its ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

this is one step towards our continued investment and commitment to the life sciences sector in Ontario, our local economy and in healthcare for all Canadians and patients around the world,” said ...

CPCT chips in financial assistance to 50 children for lifelong access to free Roche drug for SMA treatment: Our Bureau, Bengaluru Friday, November 15, 2024, 11:45 Hrs [IST] Care a ...

thanks to growth in both its pharmaceuticals and diagnostics businesses. Excluding currency movements, sales grew 9%, with increases in both divisions, Roche said.

Swiss pharma giant Roche is the latest company to refocus its R&D investment on diseases like obesity that weigh heavily on healthcare budgets. This comes as governments increasingly demand drugs ...